Meeting Report
Updates in the Management of Renal Cell Carcinoma
Kirollos S. Hanna,(1) PharmD, BCPS, BCOP, and Zita D. Lim,(2) PA-C
From (1)M Health Fairview and Mayo Clinic College of Medicine, Maple Grove, Minnesota; (2)The University of Texas MD Anderson Cancer Center, Houston, Texas
Presenters’ disclosures of conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2022;13(3):315–319 |
https://doi.org/10.6004/jadpro.2022.13.3.27 |
© 2022 Harborside™
ABSTRACT
At JADPRO Live Virtual 2021, advanced practitioner experts reviewed clinical updates in the treatment of renal cell carcinoma, key patient counseling and monitoring considerations, and best practices to manage adverse events associated with therapies for renal cell carcinoma.
For access to the full length article, please
sign in.
